

## An Efficient Asymmetric Synthesis of L- $\alpha,\omega$ -Diaminoalkanoic Acids

Zhengxin Dong

The Unit for Rational Drug Design, E-301, The University Hospital, Boston University Medical Center,  
88 East Newton Street, Boston, MA 02118, U.S.A.


**Abstract:** Efficient asymmetric syntheses of L-2,7-diaminoheptanoic acid and L-2,8-diaminooctanoic acid are described.

**2,7-Diaminoheptanoic** acid (homolysine) is a nonproteinogenic amino acid and has been widely used in **peptidomimetics** and drug design. It has served as a precursor for the syntheses of various lysine derivatives in human **renin inhibitors**<sup>1</sup> and as a lysine replacement in cyclic enkephalin<sup>2</sup> and in vasopressin analogues.<sup>3</sup>

As part of an ongoing project in this laboratory to develop highly potent and selective substrate analogue inhibitors of human tissue **kallikrein**,<sup>4</sup> we **required** optically **pure** L-homolysine and **L-2,8-diaminooctanoic** acid. In contrast to the lysine analogues **with** shorter **side** chains, the higher homologues are relatively inaccessible, especially in enantiomerically **pure** **form**. **Almost** all the synthetic methods developed in the last several decades produce **racemic** form of homolysine.<sup>5</sup> The **procedure** yielding D-homolysine **from** L-serine is lengthy and **inconvenient**<sup>6</sup>. In this communication efficient enantioselective syntheses of L-homolysine and **L-2,8-diaminooctanoic** acid are **reported**, providing a general **3-step** approach to various optically pure  **$\alpha,\omega$ -diaminoalkanoic acids**.

The protocol is based on the principle advanced by Williams, in which the configuration at the  $\alpha$  position of an  $\alpha$ -amino acid is unambiguously built up by employing a proper diphenyloxazinone as a template.<sup>7</sup> As shown in scheme I, the **diastereoselective** enolate alkylation of the **commercially** available diphenyloxazinone **1 with diiodides afforded the** alkylated oxazinone **2** ( $n=5$ : m.p.=147-148 °C,  $n=6$ : m.p.=151-152 °C) in 71-74 % yield.<sup>7</sup> Iodide **2** was then converted into axide **3** ( $n=5$ : m.p.=123-124 °C,  $n=6$ : m.p.=101-102 °C) in 87-89% by treatment with an excess of sodium axide in **DMF** at **85-90 °C** for 15 h. The removal of the **chiral-template** and the reduction of the axide functional group in axide **3** were accomplished by hydrogenation (50 psi of H<sub>2</sub>, **PdCl<sub>2</sub>, MeOH/THF/AcOH/H<sub>2</sub>O 4:4: 1: 1**, RT, 24h), producing the **desired** L-homolysine **4a**<sup>9</sup> and L-1,7-diaminooctanoic acid **4b**<sup>10</sup> in 71-78% yield.<sup>11</sup>

## Scheme I



**Acknowledgment:** I would like to thank Dr. Cathy Sultany at Ohio University for performing high temperature NMR experiments. This research is supported by NIH grant HL 38212.

## References and Notes:

- Doherty, A.M.; Kaltenbronn, J.S.; Hudspeth, J.P.; Pepine, J.T.; Roark, W.H.; Sircar, I.; Tinney, F.J.; Connolly, C.J.; Hodges, J.C.; Taylor, M.D.; Batley, B.L.; Ryan, M.J.; Essenburg, A.D.; Rapundalo, S.T.; Weishaar, R.E.; Humblet, C. and Lunney, E.A. *J. Med. Chem.* **1991**, *34*, 1258.
- Schiller, P.W.; Nguyen, T.M.-D.; Maziak, L.A.; Lemieux, C. and Wilkes, B.C. *Peptides 1986 (Proceedings of the 19th European Peptide Symposium)*; Theodoropoulos, D. Ed.; W. de Gruyter, Berlin, 1987; pp. 389-392.
- Bodanszky, M. and Lindeberg, G. *J. Med. Chem.* **1971**, *14*, 1197.
- Deshpande, M.S. and Burton, J. *J. Med. Chem.* **1992**, in press.
- Payne, L.S. and Boger, J. *Synth. Commun.* **1985**, *15*, 1277 (and references cited therein).
- Beaulieu, P.L. and Schiller, P.W. *Tetrahedron Lett.* **1988**, 2019.
- Williams, R.M. and Im, M.-N. *J. Am. Chem. Soc.* **1991**, *113*, 9276.
- $n=5$ :  $^1\text{H NMR}$  (400 MHz,  $\text{DMSO-d}_6$ , 385 K)  $\delta$  1.40-1.60 (6H, m), 2.10-2.16 (2H, dt,  $J=7.2$  Hz,  $J=7.2$  Hz), 3.31 (2H, t,  $J=6.8$  Hz), 4.81 (1H, t,  $J=7.2$  Hz). 4.92-5.08 (2H, m), 5.28 (1H, d,  $J=2.8$  Hz), 6.22 (1H, d,  $J=3.2$  Hz), 6.58 (2H, m), 7.06-7.26 (13H, m).
- $[\alpha]^{23}_{\text{D}}=+14.4$  ( $c=0.5$ , 1N HCl); m.p.=239-242 °C;  $R_f=0.35$  (silica, MeOH/AcOH 20:3, visualizing with ninhydrin);  $^1\text{H NMR}$  (400 MHz,  $\text{D}_2\text{O}$ )  $\delta$  1.31-1.33 (4H, m), 1.55 (2H, m), 1.82 (2H, m), 2.86 (2H, t,  $J=8.0$  Hz), 3.89 (1H, t,  $J=6.4$  Hz); Exact mass calculated for  $\text{C}_7\text{H}_{17}\text{N}_2\text{O}_2$  (M-2HCl + 1) m/z 161.1290, found 161.1285.
- $[\alpha]^{23}_{\text{D}}=+8.4$  ( $c=0.5$ , 1N HCl); m.p.=252-256 °C (decomposed);  $R_f=0.39$  (silica, MeOH/AcOH 20:3, visualizing with ninhydrin);  $^1\text{H NMR}$  (400 MHz,  $\text{D}_2\text{O}$ )  $\delta$  1.19-1.26 (6H, m), 1.51 (2H, m), 1.78 (2H, m), 2.85 (2H, t,  $J=7.0$  Hz), 3.87 (1H, t,  $J=4.8$  Hz); Exact mass calculated for  $\text{C}_8\text{H}_{19}\text{N}_2\text{O}_2$  (M-2HCl + 1) m/z 175.1446, found 175.1447.
- The purification of 4: a) ion-exchange chromatography on Bio-Rad AG 50W-X8, eluting with water and then 1N  $\text{NH}_4\text{OH}$ ; b) treatment with 2N HCl; and c) recrystallization from ethanol/diethyl ether.

(Received in USA 4 September 1992)